Prognostic Value of the HALP Score for One-Year Mortality or Readmission in Patients Hospitalized with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Background This study aimed to evaluate the prognostic significance of the hemoglobin-albumin-lymphocyte-platelet (HALP) score in predicting a composite outcome of all-cause mortality or chronic obstructive pulmonary disease (COPD)-related readmission within one year in patients hospitalized due to acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods In this retrospective cohort study, patients hospitalized for AECOPD at a tertiary care hospital between January 2023 and December 2024 were evaluated. 265 patients were included in the study. The HALP score was calculated using hemoglobin, albumin, lymphocyte, and platelet values at admission. The primary endpoint was defined as a composite of all-cause mortality or COPD-related readmission within one year after discharge. Independent prognostic factors were assessed using Cox proportional hazards regression, and event-free survival across HALP tertiles was compared using the Kaplan-Meier method. Results The mean age of the patients was 67.8 ± 8.3 years, and 77.4% were male. During the one-year follow-up, 128 patients (48.3%) experienced adverse clinical outcome. The HALP score was significantly lower in patients who experienced an adverse event than in those who did not [23.4 (27.3) vs. 31.1 (33.9); p = 0.02]. In multivariable Cox regression analysis, higher HALP scores were associated with a lower risk of the 1-year adverse clinical outcome (HR = 0.99; 95% CI: 0.98–1.00; p = 0.031), whereas long-term oxygen therapy was associated with an increased risk (HR = 1.78; 95% CI: 1.21–2.61; p = 0.003). One-year event-free survival differed significantly across HALP tertiles (log-rank p = 0.011), with the lowest event-free survival observed in the lowest HALP tertile. Conclusions In patients hospitalized for an AECOPD, a low HALP score, which is easily calculated from routine laboratory parameters, may serve as a practical prognostic marker that complements existing clinical and physiological assessments for long-term risk stratification.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11442846/v1
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Prognostic Value of the HALP Score for One-Year Mortality or Readmission in Patients Hospitalized with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Tarık Şimşek, Gülru Polat, Özer Özdemir, Merve Kadıoğlu
4 links
Research Square
Chronic Obstructive Pulmonary Disease (COPD) Research
preprint

Prognostic Value of the HALP Score for One-Year Mortality or Readmission in Patients Hospitalized with Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Tarık Şimşek, Gülru Polat, Özer Özdemir, Merve Kadıoğlu
preprint en

Abstract

Background This study aimed to evaluate the prognostic significance of the hemoglobin-albumin-lymphocyte-platelet (HALP) score in predicting a composite outcome of all-cause mortality or chronic obstructive pulmonary disease (COPD)-related readmission within one year in patients hospitalized due to acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods In this retrospective cohort study, patients hospitalized for AECOPD at a tertiary care hospital between January 2023 and December 2024 were evaluated. 265 patients were included in the study. The HALP score was calculated using hemoglobin, albumin, lymphocyte, and platelet values at admission. The primary endpoint was defined as a composite of all-cause mortality or COPD-related readmission within one year after discharge. Independent prognostic factors were assessed using Cox proportional hazards regression, and event-free survival across HALP tertiles was compared using the Kaplan-Meier method. Results The mean age of the patients was 67.8 ± 8.3 years, and 77.4% were male. During the one-year follow-up, 128 patients (48.3%) experienced adverse clinical outcome. The HALP score was significantly lower in patients who experienced an adverse event than in those who did not [23.4 (27.3) vs. 31.1 (33.9); p = 0.02]. In multivariable Cox regression analysis, higher HALP scores were associated with a lower risk of the 1-year adverse clinical outcome (HR = 0.99; 95% CI: 0.98–1.00; p = 0.031), whereas long-term oxygen therapy was associated with an increased risk (HR = 1.78; 95% CI: 1.21–2.61; p = 0.003). One-year event-free survival differed significantly across HALP tertiles (log-rank p = 0.011), with the lowest event-free survival observed in the lowest HALP tertile. Conclusions In patients hospitalized for an AECOPD, a low HALP score, which is easily calculated from routine laboratory parameters, may serve as a practical prognostic marker that complements existing clinical and physiological assessments for long-term risk stratification.

Research Square
HSU Dr. Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital (TR), Bakırçay Üniversitesi (TR)
Good health and well-being
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon